Harrow (HROW) Capital Expenditures Growth (3y) (2015 - 2026)
Harrow (HROW) Capital Expenditures Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 75.58% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 28.56% |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | -26.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.87% |
| Dec 31, 2025 | -27.04% |
| Sep 30, 2025 | -26.67% |
| Jun 30, 2025 | -29.14% |
| Mar 31, 2025 | -25.06% |
| Dec 31, 2024 | 117.93% |
| Sep 30, 2024 | -22.79% |
| Jun 30, 2024 | -26.81% |
| Mar 31, 2024 | -25.00% |
| Dec 31, 2023 | 33.25% |
| Sep 30, 2023 | 67.71% |
| Jun 30, 2023 | -47.45% |
| Mar 31, 2023 | 31.13% |
| Dec 31, 2022 | -0.04% |
| Sep 30, 2022 | 252.92% |
| Jun 30, 2022 | -9.61% |
| Mar 31, 2022 | 23.78% |
| Dec 31, 2021 | -41.94% |
| Sep 30, 2021 | -17.68% |
| Jun 30, 2021 | 47.51% |